JamesHDoroshowMD

Oncology • Bethesda, MD

Physician

Join to view full profile

Dr. Doroshow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Doroshow's full profile

Already have an account?

Office
3a44 Bidg 31
31 Center Drive
Bethesda, MD 20892
Phone+1 301-496-4291

Education & Training

Massachusetts General HospitalResidency, Internal Medicine, 1973 - 1975
Harvard Medical SchoolClass of 1973

Certifications & Licensure

CA State Medical License 1975 - 2026
MA State Medical License 1974 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Start of enrollment: 1996 Dec 01
Completed
Phase 1
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1996 Jun 01
Completed
Phase 2
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach Start of enrollment: 2001 Feb 01
Completed
Phase 2
Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction Start of enrollment: 2000 Feb 01
Completed
Phase 1
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer Start of enrollment: 1999 Apr 01
Completed
Phase 1
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Start of enrollment: 2009 Aug 20
Completed
Phase 2
FdCyd and THU for Advanced Solid Tumors Start of enrollment: 2012 Mar 05
Completed
Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors Start of enrollment: 2018 Nov 05
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

23 citations
Base modifications in plasmid DNA caused by potassium permanganate
Steven A. Akman, James H. Doroshow, Miral Dizdaroglu
Archives of Biochemistry and Biophysics. 1990-10-01
557 citations
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set
William C. Reinhold, Margot Sunshine, Hongfang Liu, Sudhir Varma, Kurt W. Kohn
Cancer Research. 2012-07-15
378 citations
Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-Gi
Fong-Fong Chu, James H. Doroshow, R. S. Esworthy
The Journal of Biological Chemistry. 1993-02-05

Lectures

A Novel DNA Methyltransferase Inhibitor Is Effective in an In Vivo Model of Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Pragmatica-Lung Trial Begins Enrolling Patients with NSCLC Who Did Not Respond to Previous TherapyApril 14th, 2023
Pragmatica-Lung Study, a Streamlined Model for Future Cancer Clinical Trials, Begins Enrolling PatientsApril 12th, 2023
Research Shows the Benefits of Screening AML Patients in Remission for Residual Disease Before Bone Marrow TransplantMarch 7th, 2023
Join now to see all

Grant Support

Roles Of Nadph Oxidase 5 And Dual Oxidase 2 In CancerNational Cancer Institute2010–2011
Phase 01 Clinical TrialsNational Cancer Institute2010–2011
Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyNational Cancer Institute2010–2011
Roles Of Nadph Oxidase 5 And Dual Oxidase 2 In CancerDivision Of Basic Sciences - Nci2009
Phase 01 Clinical TrialsDivision Of Basic Sciences - Nci2009
Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyDivision Of Basic Sciences - Nci2009
Phase 01 Clinical TrialsNational Cancer Institute2008
Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyNational Cancer Institute2007–2008
Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyDivision Of Basic Sciences - Nci2005–2006
Phi-39: Phase I Trial Of #7389 (Halichondrin B Analog)National Center For Research Resources2004
A Phase I Pharmacokinetic Study Of STI-571 In PatientsNational Center For Research Resources2004
CITY Of HOPE Southwest Group Clinical TrialsNational Cancer Institute1999–2004
Oncology Research Career Development ProgramNational Cancer Institute2003
Phase I Molecular And Clinical Pharmacodynamic TrialsNational Cancer Institute1999–2003
MDR1 Gene Therapy In CD34+ Cells And SCID MiceNational Cancer Institute2002
Clinical Oncology Research Career Development ProgramNational Cancer Institute1999–2002
Pharmacodynamic Phase II Breast, Lung And Ovary TrialsNational Cancer Institute1997–2001
National Cancer Institute Initial Review GroupNational Cancer Institute1999–2000
Phase I Molecular And Clinical Pharmacodynamic TrialsNational Cancer Institute1998
CITY Of HOPE Southwest Group Clinical TrialsNational Cancer Institute1998
Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–1998
Molecular Breast Cancer Therapy And CarcinogenesisNational Cancer Institute1994–1997
Southwest Oncology Group--Clinical TrialsNational Cancer Institute1993–1997
Pharmacodynamic Phase II Breast, Lung And Ovary TrialsNational Cancer Institute1994–1996
Clinical OncologyNational Cancer Institute1994–1996
Molecular Breast Cancer Therapy And CarcinogenesisNational Cancer Institute1994
Coh Clinical Oncology Research Development ProgramNational Cancer Institute1992–1993
Coh Southwest Oncology Group Clinical TrialsNational Cancer Institute1988–1992
Cancer Center Support GrantNational Cancer Institute1987–1990
Oxygen Radicals And Anticancer QuinonesNational Cancer Institute1985–1986